Neuroprotective effect of lipoxin A4 methyl ester in a rat model of permanent focal cerebral ischemia
Related Experiment Video
Updated: Jun 13, 2026
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Yan Wu1, Xi-Hong Ye, Pei-Pei Guo
1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Neuroprotective effect of lipoxin A(4) methyl ester (LXA(4) ME) was tested in a rat model of permanent middle cerebral artery occlusion. LXA(4) ME was administrated through intracerebroventricular injection immediately after middle cerebral artery was occluded. Administration of LXA(4) ME ameliorated neurological deficit, reduced infarct volume, attenuated histological damage, and decreased number of apoptotic neuron induced by ischemic insult. These neuroprotective effects of LXA(4) ME were associated with inhibition of neutrophil infiltration, lipid peroxidation, and astrocyte activation. In addition, LXA(4) ME also attenuated proinflammatory cytokines (TNF-alpha and IL-1beta) production. These data suggest that LXA(4) ME protects neuron against permanent cerebral ischemia by inhibiting inflammatory responses.
Insights
Lipoxin A(4) methyl ester (LXA(4) ME) shows neuroprotective effects in stroke models. It reduces brain damage and neuron death by inhibiting inflammation and immune cell activity.
Area of Science:
- Neuroscience
- Pharmacology
- Inflammation Research
Background:
- Stroke, particularly ischemic stroke, remains a leading cause of death and disability worldwide.
- Cerebral ischemia triggers complex inflammatory responses contributing to secondary brain damage.
- Lipoxins are endogenous anti-inflammatory mediators with potential therapeutic applications.
Purpose of the Study:
- To investigate the neuroprotective potential of lipoxin A(4) methyl ester (LXA(4) ME) in a rat model of permanent cerebral ischemia.
- To elucidate the underlying mechanisms of LXA(4) ME's neuroprotective effects.
Main Methods:
- A permanent middle cerebral artery occlusion (MCAO) model was established in rats.
- LXA(4) ME was administered intracerebroventricularly immediately after MCAO.
- Neurological deficits, infarct volume, histological damage, and neuronal apoptosis were assessed.
- Markers of inflammation, including neutrophil infiltration, lipid peroxidation, astrocyte activation, and pro-inflammatory cytokines (TNF-alpha, IL-1beta), were measured.
Main Results:
- LXA(4) ME administration significantly ameliorated neurological deficits and reduced infarct volume.
- Histological damage and the number of apoptotic neurons were attenuated by LXA(4) ME treatment.
- Neuroprotection was associated with reduced neutrophil infiltration, lipid peroxidation, and astrocyte activation.
- LXA(4) ME treatment suppressed the production of pro-inflammatory cytokines TNF-alpha and IL-1beta.
Conclusions:
- LXA(4) ME exhibits significant neuroprotective effects against permanent cerebral ischemia in a rat model.
- These protective effects are mediated by the inhibition of inflammatory responses, including neutrophil infiltration and pro-inflammatory cytokine production.
- LXA(4) ME represents a promising therapeutic candidate for treating ischemic stroke.
